Analysts noted that Evrysdi would be priced significantly lower than Biogen's Spinraza or Novartis' Zolgensma. While this will provide a market advantage, it would also yield lower per-patient revenues.
An analyst wrote that while the delay for risdiplam - prompted by Roche's submission of additional data - is unfortunate, the timing of the pivotal trials and the patient population guarantee a broad label for the drug, making the company's decision prudent.
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
The agency gave priority review to Roche's risdiplam, developed for SMA in infants and adults. The drug would potentially compete against Biogen's Spinraza and Novartis' gene therapy, Zolgensma.